Show simple item record

dc.contributor.authorPeters, Sen
dc.contributor.authorDafni, Uen
dc.contributor.authorBoyer, Men
dc.contributor.authorDe, Ren
dc.contributor.authorFaivre-Finn, Corinneen
dc.contributor.authorFelip, Een
dc.contributor.authorGarrido, Pen
dc.contributor.authorGirard, Nen
dc.contributor.authorGuckenberger, Men
dc.contributor.authorHaanen, Jen
dc.contributor.authorLe, Pen
dc.contributor.authorMornex, Fen
dc.contributor.authorOzsahin, Men
dc.contributor.authorPaz-Ares, Len
dc.contributor.authorPlanchard, Den
dc.contributor.authorRaben, Den
dc.contributor.authorRamalingam, Sen
dc.contributor.authorReck, Men
dc.contributor.authorSmit, Een
dc.contributor.authorStahel, Ren
dc.contributor.authorStenzinger, Aen
dc.contributor.authorSwanton, Cen
dc.contributor.authorVallone, Sen
dc.contributor.authorGarassino, Men
dc.date.accessioned2019-03-04T12:32:45Z
dc.date.available2019-03-04T12:32:45Z
dc.date.issued2019en
dc.identifier.citationPeters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 Jan 8.en
dc.identifier.pmid30624547en
dc.identifier.doi10.1093/annonc/mdy553en
dc.identifier.urihttp://hdl.handle.net/10541/621580
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy553en
dc.titlePosition of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).en
dc.typeArticleen
dc.contributor.departmentOncology Department, Lausanne University and CHUV, Switzerlanden
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record